Experimental pill targets tough melanoma after immunotherapy fails
NCT ID NCT07237100
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small pilot study is testing an oral drug called mirdametinib in 10 people with advanced melanoma that has a specific gene change (NF1 mutation) and has stopped responding to standard immunotherapy. The main goal is to see if the drug can shrink tumors and if it is safe enough to study further. This is an early-stage trial, so results are not yet proven.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mirdametinib (a kinase inhibitor taken by mouth)
What this could lead to
If it works, this could point toward a new treatment option for people with a specific genetic type of advanced melanoma that has stopped responding to immunotherapy.
What could go wrong
This is a very small pilot study with only 10 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
California Pacific Medical Center - Sutter Health
RECRUITINGSan Francisco, California, 94115, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact